Gilead: EU Approves the Combined Treatment of TNBC by Trodelvy and Keytruda
2026-08-24 19:19:36
According to CoinMeta, Gilead Sciences ( GILD ) announced that the European Commission has approved the combined use of Trodelvy and Keytruda for the treatment of adult patients with inoperable, locally advanced, or metastatic triple-negative breast cancer ( TNBC ).
Bullish 0
Bearish 0
Source:Internet
This content is for market information only and does not constitute investment advice.